Paper of the Month

As part of the Clinical Research Unit 5001 ResolvePAIN, we regularly feature recent publications from our scientists, which make significant contributions to the field of pain research. Our ultimate goal is to translate our experimental observations into practical therapy and eventually find new ways to “ResolvePAIN”.

March 2023

Appeltshauser L, Junghof H, Messinger J, Linke J, Haarmann A, Ayzenberg I, Baka P, Dorst J, Fisse AL, Grüter T, Hauschildt V, Jörk A, Leypoldt F, Mäurer M,  Meinl E, Michels S, Motte J, Pitarokoili K, Stettner M,  Villmann C,  Weihrauch M, Welte GS,  Zerr I, Heinze KG,  Sommer C, Doppler K 

Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage

Brain. Published online Nov 8 2022

Go to publication


In this clinical-experimental study, we described for the first time the effects of pan-neurofascin antibodies on the formation and integrity of the Ranvier Nodes. The Ranvier Nodes, that form gaps within the myelin-sheath, are crucial for the rapid conduction of action potentials. In patients with inflammatory polyneuropathies, neurofascin antibodies destroy the nodal architecture leading to impaired nerve conduction.

Our work includes a detailed description of the clinical consequences of these disorders: Affected patients suffer from an acute and severe polyneuropathy with complete paralysis of the entire musculature, including the respiratory muscles, and often need to be assisted with mechanical ventilation for prolonged periods. However, with immunomodulatory and B-cell-directed therapy, the disease is potentially reversible and usually goes into complete remission after the acute phase.


In order to better identify and efficiently treat affected patients, the accurate description of the clinical aspects of this disease is essential to everyday clinical practice. Likewise, understanding the pathomechanism of this disease allows physicians and scientists to use and further develop specific therapies for the disease. Furthermore, a cell culture model established in this study could be easily used in future studies to screen for other antibody-mediated polyneuropathies.

New biomarkers: Antibodies and neurofilament-light chain

In addition to the antibody titer, the authors also identified the neurofilament-light chain as a new biomarker of disease severity, as well as a good marker for assessing the response to long-term therapy. This will help to monitor the disease in a long term, to adjust therapies faster and to identify a possible relapse at an early stage.

Further information

Dr Kathrin Doppler, MD, is the principal investigator of Project 3, in which neuropathic pain caused by anti-Caspr2 autoantibodies is being investigated.

Dr Luise Appeltshauser, MD, works as a Clinician Scientist in the working group of Dr Kathrin Doppler and Univ.-Prof. Claudia Sommer, MD, on autoantibody-mediated neuropathies.

Previous Paper of the Month

January 2023

Schulte A, Lohner H, Degenbeck J, Segebarth D, Rittner H, Blum R, Aue A

Unbiased analysis of the dorsal root ganglion after peripheral nerve injury: no neuronal loss, no gliosis, but satellite glial cell plasticity

Pain. Published online Aug 15 2022

Go to Publication


In this paper, we describe the cellular composition of the dorsal root ganglia in an animal model of sciatic nerve injury. For the first time, deep learning (AI-based) image analysis has been applied to a large dataset of microscopy images of dorsal root ganglia. This allowed automatic evaluation of more than 2,500 immunohistochemical images of dorsal root ganglia after nerve injury - something that would have never been possible with previously used methods. As a result, we found that the nerve injury does not lead to a loss of neurons or uncontrolled growth of glial cells, as previously suspected, but only activates the cellular plasticity of glial cells.


The data published by our group sets new standards for the objective analysis of microscopic images, here representative in the research area "Molecular Pain Research". This methodology is the basis for describing the multicellular processes of pain resolution with greater precision.

Further information

In project 9 we study the multicellular processes of pain resolution. At present, even cellular processes in human dorsal root ganglia are being studied using deep learning.

November 2022

Weiner S, Strinitz M, Herfurth J, Hessenauer F, Nauroth-Kreß C, Kampf T, Homola GA, Üçeyler N, Sommer C, Pham M, Schindehütte M.

Dorsal Root Ganglion Volumetry by MR Gangliography

American Journal of Neuroradiology, Vol 43, No 5 (Mai), 2022: pp 769-775. Epub 2022 Apr 21.

Go to publication 


Several pain disorders are associated with volume changes of dorsal root ganglia which contain the cell bodies of all sensory peripheral nerve cells. They are significantly involved in pain perception and processing. In this paper, we evaluated a refined method to determine more accurately the volume of the lumbosacral dorsal root ganglia by magnetic resonance imaging (MRI). By ground-truth segmentation, the dorsal root ganglia volume in the individual segments can be determined significantly better and the DRG can be delineated more precise. In parallel, the new method was validated in a cohort of 64 healthy subjects to determine normal values of volume of dorsal root ganglia.


The investigation of the dorsal root ganglia using magnetic resonance Gangliography (MRG) provides information on the condition and function of the nervous system in humans. An improved volume determination allows early detection of changes in the dorsal root ganglia. Therefore, on the one hand, the method can play an increasingly important role in the research of painful conditions, and, on the other hand, it can also be used for diagnostics and therapy planning in the care of patients with pain disorders.

Further information

Magnetic resonance imaging of nerves is part of the projekt Z.


Portraitfoto: Univ.-Prof. Dr. med. Heike Rittner

Univ.-Prof. Dr. med.
Heike Rittner

Scientific Coordinator

+49 931 201-30251

Portraitfoto: Univ.-Prof. Dr. med. Claudia Sommer

Univ.-Prof. Dr. med.
Claudia Sommer

Speaker of the Clinical Research Unit

+49 931 201-23763